NASDAQ:SPRY ARS Pharmaceuticals Q3 2026 Earnings Date & Estimates $4.05 -0.13 (-3.11%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$4.05 0.00 (0.00%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ARS Pharmaceuticals is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026Conference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from ARS Pharmaceuticals in Q3 2026ARS Pharmaceuticals is expected to post earnings of -$0.33 per share on revenue of $42.84 million. In the same quarter a year earlier ARS Pharmaceuticals reported -$0.52 per share on revenue of $32.50 million. ARS Pharmaceuticals last reported on August 13, 2026, posting -$0.63 per share and missing the -$0.4777 consensus estimate. ARS Pharmaceuticals has beaten the consensus EPS estimate in 1 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.33Expected Revenue$42.84 millionPrior-Year EPS-$0.52Prior-Year Revenue$32.50 millionExpected Revenue Growth+31.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.63 (Missed by -$0.1523)Last Quarter Revenue$33.66 millionEPS Beat Rate1 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report ARS Pharmaceuticals Q3 2026 Earnings FAQ When does ARS Pharmaceuticals report Q3 2026 earnings? ARS Pharmaceuticals (NASDAQ:SPRY) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is ARS Pharmaceuticals' Q3 2026 earnings call? ARS Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for ARS Pharmaceuticals? Analysts expect ARS Pharmaceuticals to post earnings of -$0.33 per share for Q3 2026. How much revenue is ARS Pharmaceuticals expected to report? The consensus revenue estimate for ARS Pharmaceuticals is $42.84 million for Q3 2026. ARS Pharmaceuticals Earnings HeadlinesHead to Head Analysis: ARS Pharmaceuticals (NASDAQ:SPRY) vs. Vanda Pharmaceuticals (NASDAQ:VNDA)October 8, 2026 | americanbankingnews.comSPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026October 5, 2026 | tmcnet.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer. | Weiss Ratings (Ad)ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYOctober 5, 2026 | prnewswire.comSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawOctober 5, 2026 | prnewswire.comARS Pharmaceuticals (NASDAQ:SPRY) & Sunshine Biopharma (NASDAQ:SBFM) Critical SurveyOctober 4, 2026 | americanbankingnews.comSee More ARS Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email. Email Address About ARS PharmaceuticalsARS Pharmaceuticals (NASDAQ:SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product, neffy, is an epinephrine nasal spray designed to provide a needle-free alternative to injectable epinephrine for the emergency treatment of type I allergic reactions, including anaphylaxis. Neffy received approval from the U.S. Food and Drug Administration in 2024 for adults and children who meet the applicable weight requirements. The product is intended for use when rapid administration of epinephrine is needed and is designed to simplify delivery for patients, caregivers and health care professionals. The company has also pursued regulatory approvals and commercialization opportunities in European markets. ARS Pharmaceuticals is headquartered in San Mateo, California. The company is led by Chief Executive Officer Richard Low and continues to focus primarily on advancing its intranasal epinephrine platform and expanding access to emergency allergy treatment.View ARS Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
